Karma Biotechnologies

Karma Biotechnologies is a Los Angeles startup dedicated to solving autoimmunity, allergies, and food sensitivities with our Xavine™ precision immunotherapy platform. General immune suppression is still the standard of care for most autoimmune disease patients; there is a critical unmet need to develop antigen-specific therapies that inhibit only the disease-causing rogue immune cells. To meet this need, Karma is leveraging expertise in immunology and lipid nanoparticle engineering to develop tolerogenic immunotherapies that elicit antigen-specific immune tolerance in vivo.

Karma Biotechnologies headquartered in United States, North America, operates in the Biotechnology sector. The company focuses on Biotechnology and has secured $58.6M in funding across 12 round(s). With a team of 1-10 employees, Karma Biotechnologies is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Karma Biotechnologies, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.